[{"address1": "1-8, Doshomachi 3-chome", "address2": "Chuo-ku", "city": "Osaka", "zip": "541-0045", "country": "Japan", "phone": "81 6 6202 2161", "fax": "81 6 6229 9596", "website": "https://www.shionogi.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.", "fullTimeEmployees": 4959, "companyOfficers": [{"maxAge": 1, "name": "Dr. Isao  Teshirogi Ph.D.", "age": 64, "title": "CEO, President & Chairman", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1888768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Susumu  Mitsumori", "title": "Vice President of Finance & Accounting Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ryuichi  Kiyama Ph.D.", "title": "Senior Executive Officer & Senior VP of Administration Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Takeshi  Shiota Ph.D.", "title": "Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshimasa  Kyokawa", "title": "Vice President of Corporate Communications & Secretary Office", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Yoshihiro  Furuya", "title": "Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kohji  Hanasaki Ph.D.", "title": "Senior Executive Officer and Senior VP of Supply Supervisory Unit", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A.  Keller Ph.D.", "age": 58, "title": "Senior Executive Officer and Senior VP of R&D Supervisory Unit", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kazuhiro  Hatanaka", "title": "Senior Executive Officer & Senior VP of Corporate Strategy Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Akira  Kato Ph.D.", "title": "Senior Executive Officer & President of Shionogi Pharma Co., Ltd", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 1, "compensationRisk": 1, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 44.12, "open": 44.12, "dayLow": 44.12, "dayHigh": 44.12, "regularMarketPreviousClose": 44.12, "regularMarketOpen": 44.12, "regularMarketDayLow": 44.12, "regularMarketDayHigh": 44.12, "dividendRate": 0.73, "dividendYield": 0.015800001, "exDividendDate": 1727395200, "payoutRatio": 0.3066, "fiveYearAvgDividendYield": 1.88, "beta": 0.341, "trailingPE": 13.069015, "forwardPE": 11.775381, "volume": 2, "regularMarketVolume": 2, "averageVolume": 393, "bid": 44.09, "ask": 48.43, "bidSize": 40000, "askSize": 40000, "marketCap": 13152611328, "fiftyTwoWeekLow": 37.02, "fiftyTwoWeekHigh": 53.5, "priceToSalesTrailing12Months": 0.031067496, "fiftyDayAverage": 41.4359, "twoHundredDayAverage": 46.08567, "trailingAnnualDividendRate": 160.0, "trailingAnnualDividendYield": 3.6264734, "currency": "USD", "enterpriseValue": -239456387072, "profitMargins": 0.35456002, "floatShares": 274476898, "sharesOutstanding": 283492000, "heldPercentInsiders": 0.04837, "heldPercentInstitutions": 0.58475, "bookValue": 4492.565, "priceToBook": 0.010327063, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.28, "netIncomeToCommon": 150104997888, "trailingEps": 3.55, "forwardEps": 3.94, "pegRatio": 56104.3, "enterpriseToRevenue": -0.566, "enterpriseToEbitda": -1.562, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "SGIOF", "underlyingSymbol": "SGIOF", "shortName": "Shionogi & Co. Ltd.", "longName": "Shionogi & Co., Ltd.", "firstTradeDateEpochUtc": 1519828200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a935ff84-ae88-3f4b-a281-6a90ac9b37ba", "gmtOffSetMilliseconds": -14400000, "currentPrice": 46.395, "targetHighPrice": 11.97, "targetLowPrice": 11.97, "targetMeanPrice": 11.97, "targetMedianPrice": 11.97, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 281957007360, "totalCashPerShare": 994.586, "ebitda": 153288998912, "totalDebt": 12021999616, "quickRatio": 3.28, "currentRatio": 6.222, "totalRevenue": 423356006400, "debtToEquity": 0.931, "revenuePerShare": 1473.016, "returnOnAssets": 0.05993, "returnOnEquity": 0.11974, "operatingCashflow": 156399992832, "earningsGrowth": -0.253, "revenueGrowth": 0.158, "grossMargins": 0.86081004, "ebitdaMargins": 0.36208, "operatingMargins": 0.28807, "financialCurrency": "JPY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]